Top

Published in:

01-07-2011 | Original Paper

ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells

Authors: Emanuele Cozzani, Gian Marco Rosa, Massimo Drosera, Chiara Intra, Antonio Barsotti, Aurora Parodi

Published in: Archives of Dermatological Research | Issue 5/2011

Abstract

Drug-induced pemphigus has been reported in patients receiving angiotensin-converting enzyme inhibitors. The aim of this work was to study a group of hypertensive patients without skin diseases treated with angiotensin-converting enzyme (ACE) Inhibitors (I), to verify the presence of serum circulating anti-antibodies. The indirect immunofluorescence showed that 33 sera (52.38%) presented autoantibodies directed to an antigen of the cytoplasm of the superficial epidermal keratinocytes. Two of the 33 positive sera had antibodies to Dsg1 and/or 3 in ELISA. Immunoblot analyses were negative. All the 48 control sera were found to have no circulating antibodies using the three assays. Our results would confirm that ACEI drugs may trigger the production of circulating autoantibodies also in patients without clinical manifestations of pemphigus.

Amagai M, Komai A, Hashimoto T et al (1999) Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140:351–357PubMedCrossRef

Brenner S, Wolf R, Ruocco V (1993) Drug-induced pemphigus. I. A survey. Clin Dermatol 11:501–505PubMedCrossRef

Brenner S, Bialy-Golan A, Ruocco V (1998) Drug-induced pemphigus. Clin Dermatol 16:393–397PubMedCrossRef

Cirillo N, Femiano F, Gombos F, Lanza A (2009) High-dose pemphigus antibodies against linear epitopes of desmoglein 3 (Dsg3) can induce acantholysis and depletion of Dsg3 from keratinocytes. Immunol Lett 122:208–213PubMedCrossRef

Cozzani E, Kanitakis J, Nicolas JF et al (1994) Comparative study of indirect immunofluorescence and immunoblotting for the diagnosis of autoimmune pemphigus. Arch Dermatol Res 286:295–299PubMedCrossRef

De Angelis E, Lombardi ML, Grassi M et al (1992) Enalapril: a powerful in vitro non-thiol acantholytic agent. Int J Dermatol 31:722–724PubMedCrossRef

Godard W, Lambert D, Gavanou J et al (1980) Pemphigus induced by treatment with a propanolol–meprobamate combination. Ann Dermatol Venereol 107:1213–1216PubMed

Jiao D, Bystryn JC (1997) Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. J Am Acad Dermatol 37:211–216PubMedCrossRef

Kaplan RP, Potter TS, Fox JN (1992) Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 26:364–366PubMedCrossRef

10.

König C, Eickert A, Scharfetter-Kochanek K et al (2001) Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol 44:689–692PubMedCrossRef

11.

Korman NJ, Eyre RW, Zone J et al (1991) Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 96:273–276PubMedCrossRef

12.

Kuechle MK, Hutton KP, Muller SA (1994) Angiotensin-converting enzyme inhibitor-induced pemphigus three case reports and literature review. Mayo Clin Proc 69:1166–1171PubMed

13.

Lo Schiavo A, Guerrera V, Cozzani E et al (1999) In vivo enalapril-induced acantholysis. Dermatology 198:391–393PubMedCrossRef

14.

Müller R, Svoboda V, Wenzel E et al (2008) IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol 17:35–43PubMed

15.

Ruocco V, Pisani M, de Angelis E et al (1990) Biochemical acantholysis provoked by thiol drugs. Arch Dermatol 126:965–966PubMedCrossRef

16.

Ruocco V, de Angelis E, Lombardi ML et al (1988) In vitro acantholysis by captopril and thiopronine. Dermatologica 176:115–123PubMedCrossRef

17.

Sharma PM, Choi EJ, Kuroda K, Hachiya T et al (2009) Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3. J Invest Dermatol 129:2309–2312PubMedCrossRef

18.

Su H, Reano A, Viac J, Thivolet J (1989) Comparative expression of bullous pemphigoid antigens in normal human epidermis and cultured keratinocytes. Clin Immunol Immunopathol 5:406–413CrossRef

19.

Yamagami J, Kacir S, Ishii K et al (2009) Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183:5615–5621PubMedCrossRef

20.

Yokel BK, Hood AF, Anhalt GJ (1989) Induction of acantholysis in organ explant culture by penicillamine and captopril. Arch Dermatol 125:1367–1370PubMedCrossRef

21.

Yokouchi M, Saleh MA, Kuroda K et al (2009) Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J Invest Dermatol 129:2156–2166PubMedCrossRef

Title: ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells
Authors: Emanuele Cozzani
Gian Marco Rosa
Massimo Drosera
Chiara Intra
Antonio Barsotti
Aurora Parodi
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Archives of Dermatological Research / Issue 5/2011
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-010-1060-5

At a glance: The STEP trials

Springer Medicine

ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Plasma cluster ions decrease the antigenicity of mite allergens and suppress atopic dermatitis in NC/Nga mice

Tea tree oil attenuates experimental contact dermatitis

Seven novel mutations in the ATP2A2 gene of Austrian patients with Darier’s disease

Comparative toxicity of oxygenated monoterpenoids in experimental hydroalcoholic lotions to permethrin-resistant adult head lice

Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA

Dermal substitute-assisted healing: enhancing stem cell therapy with novel biomaterial design